Xenon Pharmaceuticals Inc.
↗Burnaby, Canada
Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for patients with neurological and psychiatric disorders. The company leverages its expertise in ion channel biology to discover and develop novel treatments for conditions such as epilepsy, major depressive disorder, and bipolar depression.
Xenon's pipeline is centered on ion channel modulators, including its lead candidate, azetukalner (a Kv7 potassium channel opener), which is in late-stage clinical development. The company maintains a strategic approach to drug development, combining internal discovery efforts with collaborations with larger pharmaceutical partners to advance its therapeutic programs.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Revenue:$5M-$10M
Founded:1996
Ownership:public
Status:operating
FUNDING
Stage:Public
STOCK
Exchange:NASDAQ
Ticker:XENE
Market Cap:$5.3B
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3
Modalities:Small molecule
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Neurocrine Biosciences (Collaboration for NBI-921352)
COMPETITION
Position:Emerging
Competitors:UCB, Jazz Pharmaceuticals, Sage Therapeutics
LEADERSHIP
Key Executives:
Ian Mortimer - CEO
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Xenon Pharmaceuticals Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Xenon Pharmaceuticals Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.